The invention is generally directed to promoting dendritic cells (DCs), and optionally M1-type (macrophage M1 polarization), immune response by administering a compound that modulates macrophage polarization. The invention is directed to the use of an antibody able to bind to CSF-1R for modulating macrophage polarization. The invention is also directed to methods for evaluating the dose efficacy of an antibody able to bind to CSF-1R in a patient by assessing the in vivo or in vitro polarization of macrophages. The invention is further directed to post-treatment companion test and assays to assess the effect of an antibody able to bind to CSF-1R on a subject being treated.一般而言,本發明係關於藉由投與調節巨噬細胞極化之化合物來促進樹狀細胞(DC)、且視情況M1型(巨噬細胞M1極化)免疫反應。本發明係關於能夠結合至CSF-1R之抗體用於調節巨噬細胞極化之用途。本發明亦係關於用於在患者中評價能夠結合至CSF-1R之抗體之劑量效力的方法,其係藉由評估巨噬細胞之活體內或活體外極化來達成。本發明進一步係關於評估能夠結合至CSF-1R之抗體對所治療個體之效應之治療後伴隨式測試(companion test)及分析。
